U.S. stock futures were mixed this morning, with the Nasdaq 100 futures gaining more than 50 points on Tuesday.

Shares of JPMorgan Chase & Co. (NYSE:JPM) fell in pre-market trading following first-quarter results.

JPMorgan Chase reported quarterly earnings of $5.94 per share which beat the analyst consensus estimate of $5.45 per share. The company reported quarterly sales of $50.536 billion which beat the analyst consensus estimate of $49.169 billion.

JPMorgan shares dipped 3.1% to $303.81 in pre-market trading.

Here are some other stocks moving lower in pre-market trading.

• Newsmax Inc (NYSE:NMAX) fell 7.7% to $5.84 in pre-market trading. Newsmax, last month, reported better-than-expected fourth-quarter financial results and issued FY26 sales guidance above estimates.
• Falcon’s Beyond Global Inc (NASDAQ:FBYD) fell 6.3% to $11.89 in pre-market trading. Falcon’s Beyond Global, last month, reported a year-over-year increase in its fourth-quarter financial results.
• Telix Pharmaceuticals Limited (NASDAQ:TLX) fell 5.9% to $10.59 in pre-market trading. Telix Pharmaceuticals shares gained around 7% on Monday following a significant collaboration announcement with Regeneron Pharmaceuticals Inc. (NASDAQ:REGN).
• Allogene Therapeutics, Inc. (NASDAQ:ALLO) declined 4.8% to $2.91 in pre-market trading after the company announced a $175 million public stock offering.
• Valley National Bancorp (NASDAQ:VLY) fell 4.7% to $12.50 in pre-market trading.
• British American Tobacco p.l.c. (NYSE:BTI) fell 3.7% to $56.51 in pre-market trading.
• Mega Fortune Company Limited (NASDAQ:MGRT) fell 3.1% to $47.72 in pre-market trading.
• HMH Holding Inc. (NASDAQ:HMH) dipped 3% to $18.39 in pre-market trading.
• CarMax, Inc. (NYSE:KMX) slipped 2.2% to $48.00 in pre-market trading ahead of quarterly earnings.

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.